Search

The integration of artificial intelligence (AI) into in-hospital clinical decision systems has revolutionized patient care, yet challenges persist in ensuring explainability, managing risks, and establishing robust governance. This conceptual manuscript proposes the explainable risk governance orchestration framework (ERGOF), a novel model designed to orchestrate risk intelligence within clinical environments. ERGOF emphasizes layered architectures that integrate data interoperability, real-time risk assessment, explainable decision pipelines, and adaptive governance mechanisms to mitigate biases and enhance trustworthiness. Drawing from theoretical foundations in healthcare informatics and AI ethics, the framework addresses key gaps in current systems, such as opaque decision-making and fragmented oversight. Through interpretive formulas for risk propagation and governance load, ERGOF illustrates how explainable intelligence can be embedded in clinical workflows without empirical validation. The model promotes seamless integration with electronic health records (EHRs) and decision support tools, fostering human-AI collaboration in high-stakes settings like intensive care units. By prioritizing transparency and accountability, ERGOF offers a pathway for sustainable AI deployment in hospitals, potentially reducing clinical errors and improving outcomes. This work synthesizes recent literature to advocate for governance-centric designs, highlighting the need for interdisciplinary approaches in AI-driven healthcare. Ultimately, ERGOF serves as a blueprint for future systems that balance innovation with ethical imperatives in clinical decision-making.

The integration of artificial intelligence (AI) into healthcare systems has revolutionized clinical analytics, enabling enhanced diagnostic accuracy, predictive modeling, and personalized treatment pathways. However, the opacity of many AI models poses significant challenges to their clinical adoption, necessitating advancements in explainable AI (XAI) to ensure interpretability and transparency. This narrative review synthesizes the literature on XAI within clinical systems, focusing on interpretability mechanisms, transparency frameworks, and deployment constraints in healthcare analytics. Drawing from high-impact studies, we examine how XAI addresses the “black box” nature of machine learning models in high-stakes medical decisions, particularly in contexts where performance has traditionally been prioritized over explainability. Key themes include the shift toward inherently interpretable models for critical applications, such as diagnostic imaging and predictive analytics, where post-hoc explanations often fall short. We explore the ethical imperatives for responsible AI deployment, including strategies for mitigating harm through transparent systems that align with clinical workflows. The review integrates perspectives on XAI in clinical diagnostics, emphasizing challenges in balancing model complexity with user trust. Transparency is framed not merely as a technical feature but as a systemic requirement, incorporating structured reporting practices for AI interventions and standardized modeling approaches. Deployment constraints are analyzed through the lens of real-world integration, including regulatory considerations, data privacy concerns, and human–AI interaction dynamics in healthcare infrastructures. We synthesize evidence from diverse applications, such as lung cancer diagnosis via explainable models and radiographic assessments, underscoring the need for multidisciplinary approaches to XAI. Furthermore, the review highlights biases in AI systems, particularly sex and gender disparities, and advocates for inclusive analytics to foster equitable healthcare. Clinical applications beyond the black box are discussed, with calls for standardized reporting to enhance reproducibility and trust. We position XAI as essential for closed-loop systems that incorporate feedback mechanisms, ensuring ongoing model recalibration in dynamic clinical environments. The synthesis reveals persistent gaps in current XAI deployments, such as overreliance on surrogate explanations that may mislead clinicians. Ultimately, this review proposes a systems-level framework for XAI in healthcare, integrating data ingestion, inference, decision support, and governance loops to overcome transparency barriers. This comprehensive overview informs the development of future AI-enabled healthcare infrastructures, emphasizing interpretability as a cornerstone for safe and effective clinical analytics.

In the evolving landscape of healthcare systems, predicting and managing patient length-of-stay (LOS) remains pivotal for operational efficiency. Yet, traditional models often overlook the interplay of real-time constraints and explainability. This conceptual manuscript introduces the constrained flow dynamics integrator (CFDI), a semi-mechanistic framework designed to model patient flow under operational constraints while prioritizing interpretability. Grounded in theoretical architectures from clinical AI and healthcare analytics, the CFDI integrates modular layers for constraint mapping, mechanistic simulation, and explainable inference, enabling hypothetical orchestration of patient trajectories without empirical data. By incorporating feedback topologies that simulate governance and interoperability, the framework addresses challenges in electronic health record (EHR) ecosystems and decision support pipelines. Conceptual formulas capture risk propagation across constrained environments and decision confidence in flow modeling, offering interpretive insights into resource allocation and monitoring burdens. This work synthesizes recent literature on AI governance and workflow integration, proposing a unique system for theoretical patient flow optimization. Implications extend to enhanced infrastructural resilience in healthcare settings, fostering transparent analytics amid operational pressures. Ultimately, the CFDI advances conceptual paradigms for explainable modeling, bridging gaps in constrained healthcare intelligence without relying on performance metrics or simulations.

Care pathways represent the temporal sequences of clinical events that define real-world patient journeys within complex healthcare systems. Recent advances in artificial intelligence have enabled the analysis of these pathways through sequence analytics, uncovering latent patterns beyond traditional guideline-based approaches. This narrative review synthesizes literature to examine three pillars of AI-enabled care pathway analytics: clustering methods that group similar patient trajectories, deviation detection techniques that identify meaningful variations from expected flows, and interpretability frameworks that support transparency and clinician trust.Drawing on process mining, sequence analysis, and explainable AI, the review highlights how electronic health record data can be transformed into actionable insights for clinical decision-making. Clustering approaches reveal hidden patient subgroups across domains such as oncology, cardiology, mental health, and critical care. Deviation detection methods expose bottlenecks, workarounds, and non-adherence associated with adverse outcomes and inefficiencies. Interpretability frameworks link algorithmic outputs to clinical logic, improving trust and adoption in healthcare settings.Cross-study evidence shows that while clustering and deviation detection methods have advanced significantly, their integration with interpretability remains limited, constraining large-scale implementation. The review proposes an integrative systems perspective that positions care pathway sequence analytics as a foundational component of AI-enabled healthcare infrastructure, encompassing data pipelines, model inference, intervention orchestration, and governance. Overall, AI-driven pathway analytics offers the potential to move healthcare from reactive, guideline-based care toward proactive, personalized, and continuously learning systems.

Heart failure affects over 6 million Americans, with 30-day readmission rates remaining 20–25% despite longstanding quality improvement efforts. These readmissions cost about $17 billion annually and are penalized under federal reimbursement programs, yet existing prediction models have not achieved clinically useful performance. Most current models treat patients independently and fail to capture meaningful relationships among patients with similar medication patterns, admission histories, and social circumstances. They also often exclude critical social determinants of health (SDOH), such as housing instability and food insecurity, despite their strong association with readmission risk. In addition, black-box models lack interpretability, limiting clinician trust and usability. I argue that explainable graph neural networks (GNNs) integrating clinical data, SDOH, and prior admissions should replace traditional logistic regression and tree-based models for readmission prediction. Patient similarity graphs can represent clinically relevant relationships that tabular models miss, while graph attention mechanisms provide interpretable, actionable explanations. GNNs enable direct integration of SDOH and prior utilization patterns and offer transparency by highlighting which similar patients most influence predictions. This makes them more suitable for clinical decision support than existing approaches. Overall, persistent readmission rates reflect limitations in current modeling strategies. Explainable GNNs provide a more clinically meaningful and policy-relevant approach to improving prediction and reducing preventable readmissions.

The integration of artificial intelligence into clinical decision support systems offers improved diagnostic accuracy and efficiency, but the opacity of many machine learning models raises concerns about trust, accountability, and regulatory compliance. Explainable artificial intelligence (XAI) has been proposed to address this by making model predictions interpretable to clinicians; however, its true clinical value remains uncertain, and evaluation has not kept pace with methodological development. This systematic review aimed to identify XAI methods used in clinical decision support systems, assess how they are evaluated with clinicians, and determine whether explanations improve diagnostic accuracy, trust, mental models, and efficiency. Following PRISMA guidelines, we searched PubMed, Web of Science, IEEE Xplore, ACM Digital Library, and Scopus for studies published between 2017 and 2024. Eligible studies included original research evaluating XAI in clinical decision support systems with clinician participants and reporting quantitative or qualitative outcomes. Risk of bias was assessed using adapted QUADAS-2 and ROBIS tools, and findings were synthesized narratively with subgroup analyses. From 2,847 records, 68 studies were included. The most common XAI methods were SHAP-based feature attribution (38%), saliency or heatmap methods (29%), concept-based approaches such as TCAV (15%), and counterfactual or example-based explanations (12%). Radiology was the dominant field (54%), followed by dermatology (18%) and pathology (12%). Evaluation approaches were highly inconsistent, with few validated instruments and most studies relying on Likert-scale trust measures or qualitative feedback. Only 16% of studies showed improved diagnostic accuracy with explanations, 67% showed no significant effect, and 17% reported reduced accuracy due to over-reliance or misinterpretation. Although 82% of studies reported increased clinician trust, trust rarely correlated with actual diagnostic performance. Overall, while XAI methods are widely studied in clinical decision support, their evaluation is inconsistent and their benefits are limited. Explanations tend to increase clinician trust without reliably improving diagnostic accuracy, and may sometimes worsen performance, highlighting a trust–accuracy gap that poses important safety concerns for clinical deployment.

Prostate cancer metastasis to bone and lymph nodes marks a critical transition to incurable disease, with five-year survival dropping dramatically compared to localized disease. Early identification of patients at high risk of metastasis enables timely intensification of treatment, including androgen deprivation therapy, salvage radiation, or systemic therapies. Current deep survival models that integrate serial PSA measurements and genomic risk scores achieve high predictive accuracy for time-to-metastasis but operate as black boxes, providing no explanation for why a particular patient is predicted to have early or late metastasis. Clinicians cannot trust or act upon predictions without understanding which PSA features or genomic markers drive the risk assessment. We present an explainable deep survival framework that combines a deep survival model for time-to-metastasis prediction with Integrated Gradients attribution, a method that distributes the model's hazard prediction among input features. The framework produces patient-specific explanations showing how each serial PSA value and each genomic score component contributes to the predicted metastasis hazard. The framework consists of three core components: (1) a deep survival model (DeepSurv architecture) with a PSA time-series encoder and genomic risk encoder, (2) Integrated Gradients attribution computed over the hazard function, and (3) visualization tools for individual and population-level interpretations. Integrated Gradients attributes the predicted hazard to individual PSA measurements across time and specific genomic markers, enabling clinicians to distinguish between risk driven by rapid PSA kinetics versus high genomic risk scores. This interpretability transforms a black-box survival prediction into an actionable clinical decision support tool.